This product is a calcium influx blocker or slow channel blocker, which blocks calcium ions from entering cells through the channels on the myocardial or vascular smooth muscle membrane, thereby causing the vascular tension of the whole body, including the coronary arteries, to decrease and expand, thus lowering blood pressure. It increases the blood supply of the coronary arteries. On the other hand, it can inhibit myocardial contraction, reduce myocardial work, reduce oxygen demand, and relieve angina pectoris. The therapeutic dose has little effect on the function of the sinoatrial node and atrioventricular node.

It inhibits the synthesis and release of prostaglandins in the hypothalamus, restores the normal responsiveness of the receptor neurons in the body temperature regulation center, and has an antipyretic effect; it has an analgesic effect by inhibiting the synthesis of prostaglandins, etc.; it inhibits the synthesis and release of prostaglandins in local inflammatory tissues, stabilizes lysosomal enzymes, and affects the phagocytic function of macrophages, thereby playing an anti-inflammatory role.

It is a peripheral analgesic that inhibits the synthesis and release of prostaglandins (PGE1) in the hypothalamic temperature regulation center, causing peripheral vasodilation and sweating to achieve an antipyretic effect; at the same time, it can inhibit the effects of PGE1, bradykinin and histamine, increase the pain threshold and produce analgesic effect.

It is a central nervous system stimulant that can excite the cerebral cortex, increase sensitivity to the outside world, and constrict cerebral blood vessels, thereby enhancing the effect of the first two drugs in relieving headaches.

It has a strong histamine H1 receptor blocking effect, can alleviate other respiratory symptoms caused by allergies, and also has a mild inhibitory effect on the central nervous system.

This product is a fluoroquinolone antibacterial drug with a broad-spectrum antibacterial effect, especially high antibacterial activity against aerobic Gram-negative bacteria. It has good antibacterial activity against the following bacteria in vitro: most bacteria of the Enterobacteriaceae family, including Citrobacter, Enterobacter cloacae, Enterobacter aerogenes and other Enterobacter species, Escherichia coli, Klebsiella, Proteus, Salmonella, Shigella, Vibrio, Yersinia, etc. Norfloxacin also has antibacterial activity against multi-drug resistant bacteria in vitro. It also has good antibacterial effects on penicillin-resistant Neisseria gonorrhoeae, Haemophilus influenzae and Moraxella catarrhalis. Norfloxacin is a bactericide that acts on the A subunit of bacterial DNA helicase, inhibiting DNA synthesis and replication, leading to bacterial death.

This product is a dopamine 2 (D2) receptor antagonist, and also has a 5-hydroxytryptamine 4 (5-HT4) receptor agonist effect, and has a mild inhibitory effect on 5-HT3 receptors. It can act on dopamine receptors in the medullary emetic chemoreceptor zone (CTZ) to increase the threshold of CTZ, and has a strong central antiemetic effect. This product can also block hypothalamic dopamine receptors, inhibit prolactin inhibitory factor, and promote the secretion of prolactin, so it has a certain lactation effect. The inhibitory effect on other parts of the central nervous system is relatively small, with a weak sedative effect and less hypnotic effect. The effect on the gastrointestinal tract is mainly in the upper digestive tract, promoting the movement of the stomach and upper intestinal segments; increasing the tension of the gastrointestinal sphincter in the resting state, increasing the tension and contraction amplitude of the lower esophageal sphincter, and increasing the pressure at the lower end of the esophagus.

This product is a nitroimidazole derivative that can inhibit the redox reaction of amoeba and break the nitrogen chain of the protozoa. In vitro tests have shown that when the drug concentration is 1~2mg/L, the histolytica amoeba can undergo morphological changes in 6~20 hours and all are killed within 24 hours. When the concentration is 0.2mg/L, the histolytica amoeba can be killed within 72 hours. This product has a strong effect of killing trichomonas, and its mechanism is unknown. Metronidazole has a killing effect on anaerobic microorganisms, and the metabolites generated when it is reduced in the human body also have anti-anaerobic effects, inhibiting the synthesis of bacterial deoxyribonucleic acid, thereby interfering with the growth and reproduction of bacteria, and ultimately causing bacterial death. It has a carcinogenic effect on some animals.